Bibliography,Species,Refid,Publicationyear,Modelsystem,Strainorpatienttype,Sex,Age,Route,Duration,Durationunit,Drug,Purity,Control,Vehicle,Compound,Endpointtype,Endpointname,Endpointunits,Tissue.sex,DailyDose,UnitofDose,Timepoint,Numberofexperimentalunits.animals.humans.,Effectvalue,Variability,UnitofVariability,note,Histopathcall,study_ID
"Chiang, C. K.,Ho, T. I.,Peng, Y. S.,Hsu, S. P.,Pai, M. F.,Yang, S. Y.,Hung, K. Y.,Wu, K. D..  Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care.  2007. 30:3-7",Human,65,2007,Human prospective cohort study,Taiwanese hemodyalysis patients,Male + Female,Mean age of 56.8 years,p.o.,12,Months,Rosiglitazone/Avandia,,Baseline,,Rosiglitazone/Avandia,LFT,ALT,IU/L,,0,IU/L,Month 12 (Study end),72,13.4,4.8,SD,NA,NA,3
"Chiang, C. K.,Ho, T. I.,Peng, Y. S.,Hsu, S. P.,Pai, M. F.,Yang, S. Y.,Hung, K. Y.,Wu, K. D..  Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care.  2007. 30:3-7",Human,65,2007,Human prospective cohort study,Taiwanese hemodyalysis patients,Male + Female,Mean age of 56.8 years,p.o.,12,Months,Rosiglitazone/Avandia,,Baseline,,Rosiglitazone/Avandia,LFT,ALT,IU/L,,5,IU/L,Month 12 (Study end),72,11.2,5.7,SD,NA,NA,3
